iRadimed Corporation (NASDAQ:IRMD – Get Free Report) announced a quarterly dividend on Tuesday, February 10th. Shareholders of record on Monday, February 23rd will be paid a dividend of 0.20 per share by the medical equipment provider on Friday, March 6th. This represents a c) annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Monday, February 23rd. This is a 17.6% increase from iRadimed’s previous quarterly dividend of $0.17.
iRadimed has a payout ratio of 34.2% meaning its dividend is sufficiently covered by earnings. Analysts expect iRadimed to earn $2.00 per share next year, which means the company should continue to be able to cover its $0.68 annual dividend with an expected future payout ratio of 34.0%.
iRadimed Trading Up 9.6%
IRMD opened at $105.15 on Wednesday. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of 63.73 and a beta of 1.11. iRadimed has a 12-month low of $47.48 and a 12-month high of $107.90. The business’s fifty day simple moving average is $98.08 and its 200-day simple moving average is $83.43.
About iRadimed
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Featured Stories
- Five stocks we like better than iRadimed
- Nvidia CEO Issues Bold Tesla Call
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
